Correction to: Veterinary Research Communications

The following errors are listed as follows:

Figures 3D and E depict representative images of BV-2 microglial cells that were protected by lobetyolin against OGD/R. The concentrations of lobetyolin in these images are 1.0 µM and 10.0 µM, respectively.

Figures 9A and 9B show two phenotypes of BV-2 microglial cells polarized into M1 and M2 types after polarization, with M1 phenotype marker CD16 + 32 and M2 phenotype marker CD206 immunofluorescently labeled in red. The green images represent representative immunofluorescent images of Iba1-labeled microglial cells. After damage from ischemia-reperfusion injury, microglial cells can differentiate into two phenotypes, with a particularly significant increase in CD16 + 32. Lobetyolin can alter this trend and increase the number of CD206 phenotypes.

The revised Figs. 9A and 9B did not affect the trend of the previous statistical charts, except that the statistical results of the high dose of lobetyolin in Fig. 9B changed from P < 0.01 to P < 0.001, which did not affect the overall conclusion of the charts. The original images for Fig. 9, along with their corresponding data analyses, have been attached to the email for your review.

The errors in Figs. 3D & E, and 9A and B resulted from oversight during the image preparation process. Re-The revised Figs. 9A and 9B did not affect the trend of the previous statistical charts, except that the statistical results of the high dose of lobetyolin in Fig. 9B changed from P < 0.01 to P < 0.001, which did not affect the overall conclusion of the charts. Overall conclusions remain largely unchanged. We sincerely apologize for any inconvenience and confusion this may have caused.

Effect of lobetyolin on the morphological changes in BV2 cells of (A) control group; (B) oxygen–glucose deprivation/reperfusion (OGD/R) model group; (C) low-dose lobetyolin group (0.1 µM, cells pretreated for 2 h before OGD/R); (D) medium-dose lobetyolin group (1.0 µM, cells pretreated for 2 h before OGD/R); (E) high-dose lobetyolin group (10.0 µM, cells pretreated for 2 h before OGD/R); and (F) edaravone group (10.0 µM, cells pretreated for 2 h before OGD/R). (G) Cell viability was assessed using the Cell Counting Kit-8 assay. (H) Cell density with amoeba-like microglia (cells/µm2). The values are expressed as mean ± standard error of the mean (n = 6). The statistical analyses were performed using a one-way analysis of variance, followed by the Newman–Keuls post-hoc test. ## indicates P < 0.01 versus control group; * indicates P < 0.05 versus OGD/R group; and ** indicates P < 0.01 versus OGD/R group

Lobetyolin and edaravone (Eda) modulate the oxygen–glucose deprivation/reperfusion (OGD/R) -induced polarization in BV2 microglia. Representative photomicrographs of double-staining immunofluorescence of CD16/32 with Iba1 and CD206 with Iba1 in OGD/R-injured BV2 microglia. Quantitative analysis of CD16/32-positive and CD206-positive BV2 microglia. Values are expressed as the Mean ± SEM (n = 3). Statistical analyses were performed using One-way ANOVA followed by Newman–Keuls post-test.###P < 0.001 versus control;*P < 0.05 versus OGD/R group;**P < 0.01 versus OGD/R group;***P < 0.001 versus OGD/R group